Currently browsing tag

alzheimer

Nestle pushes further into medicine with planned Alzheimer’s test

Food group Nestle has taken a further step into the medicine business by signing a research collaboration agreement with a Swiss biotech company to develop an Alzheimer’s disease diagnostic test. Nestle’s second medical deal in a week underscores the commitment by the world’s largest packaged food company to the faster-growing, more profitable medical field as sales of processed foods slow in many markets. Tau is a protein that causes tangles in the brain that are a hallmark of Alzheimer’s. The Swiss food maker said last week it had signed a separate deal to develop a new treatment for ulcerative colitis.

Dementia may be stabilising in some countries: study

The occurrence of dementia and Alzheimer's disease may have stabilised in some wealthy nations, according to a study released Friday. A review of data from Sweden, the Netherlands, Britain and Spain showed the percentage of the population with dementia — the umbrella term for neurodegenerative diseases of the brain — holding steady, along with the number of new cases, said the study, published in The Lancet Neurology. Researchers led by Carol Brayne, a professor at the Cambridge Institute of Public Health and the University of Cambridge, compared dementia occurrence in old people across two time periods spanning the last several decades.

Judge rules Alzheimer’s project belongs to UC San Diego

LOS ANGELES (AP) — A judge has ruled that control of a landmark project on Alzheimer’s disease belongs to the University of California, San Diego — handing the school a major victory in its lawsuit against the University of Southern California.

Ahead of Alzheimer’s meeting, researchers seize on signs of progress

By Bill Berkrot and Ransdell Pierson NEW YORK (Reuters) – After decades of Alzheimer’s research that led to dead ends, including 123 drugs that failed, top researchers in the field say they are far more confident now of producing an effective treatment. New experimental drugs from Eli Lilly and Co and Biogen have shown promise in slowing down the progression of the mind-wasting disease, attracting the attention of investors and patients. “The recurring platitude, which has been going on forever is ‘gee we’re about five years away from a really effective treatment,'” said Steven Ferris, who directs the Alzheimer’s clinical trials program at NYU Langone Medical Center in New York.

Judge halts Alzheimer’s drug swap until July

ALBANY, N.Y. (AP) — A federal judge on Monday ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer’s medication, allegedly in an effort to drive patients to a newer patented drug.